What makes a test “molecular”?
This is the idea behind molecular point-of-care testing (molecular POCT).
Rather than describing one particular technology or instrument, molecular POCT represents a testing model in which molecular detection is performed at or near the point of patient care using workflows designed for more decentralised operation.
Molecular diagnostic tests detect biological targets at the nucleic-acid level—DNA or RNA.
Nucleic acid amplification tests (NAATs) use amplification technologies to make target genetic material detectable. PCR is one of the best-known approaches, although other amplification technologies also exist.
This ability to detect pathogen nucleic acids has made molecular diagnostics important across many areas of infectious-disease testing.
Traditional molecular workflows, however, may involve several separate steps:
Depending on the laboratory and assay, these steps may require multiple instruments, dedicated work areas and trained molecular laboratory personnel.
Molecular POCT attempts to simplify this journey.
From multi-step laboratory testing to integrated testing
A useful way to understand molecular POCT is to compare the workflow rather than simply comparing instruments.
Conventional Multi-Step Molecular Workflow
Different systems may automate some of these steps, but conventional molecular laboratories can still require multiple workflow stages.
Integrated Molecular POCT Workflow
The exact workflow varies by platform.
Integration changes the workflow — and can change where molecular testing can be performed.
The important concept is integration: processes that traditionally required separate laboratory steps can increasingly be combined within cartridges, consumables or automated systems.
This can reduce hands-on complexity and change where molecular testing can realistically be performed.
Point-of-care, near point-of-care and central laboratory testing
These terms describe different testing models rather than a simple hierarchy of better and worse.
Central Laboratory
Laboratory capability, scale and testing breadth
Near Point-of-Care
Brings molecular capability closer to clinical services
Point-of-Care
Potentially shortens the pathway between testing and clinical action
| Aspect | Central Laboratory | Near Point-of-Care | Point-of-Care |
|---|---|---|---|
| Typical location | Molecular laboratory | Peripheral/decentralised laboratory or near clinical service | At or close to patient-care setting |
| Workflow | May involve multiple separate processes | Usually simplified or integrated | Designed for highly simplified near-patient operation |
| Operator requirements | Typically trained laboratory personnel | Depends on platform and setting | Designed to reduce technical complexity, subject to intended use |
| Infrastructure | Laboratory infrastructure | Reduced infrastructure may be possible | Minimal or decentralised infrastructure may be possible |
| Testing model | Centralised | Decentralised / near-patient | Point of clinical need |
| Main strength | Laboratory capability, scale and testing breadth | Brings molecular capability closer to clinical services | Potentially shortens the pathway between testing and clinical action |
The boundaries are not always absolute. A compact sample-to-result molecular system might operate as a POCT platform in one healthcare system but be placed within a decentralised laboratory in another.
Therefore, the testing environment and implementation model matter as much as the physical size of the instrument.
Is molecular POCT the same as a rapid test?
Not necessarily.
“Rapid test” describes how quickly a result can be obtained. “Point-of-care” describes where and how testing is delivered.
Likewise, molecular testing describes the underlying detection approach.
A test can therefore be:
Rapid
Describes speed / time to result
Point-of-Care
Describes where and how testing is delivered
Molecular
Describes the diagnostic detection approach
These terms should not automatically be used interchangeably.
What does “sample-to-result” mean?
Sample-to-result—or sample-to-answer—is commonly used to describe systems that integrate much of the analytical workflow between loading a specimen and generating a result.
Conceptually:
Sample-to-Result — Conceptual Workflow
- 1Specimen
- 2Closed / Integrated Process
- 3Molecular Detection
- 4Result
Sample-to-result does not automatically mean zero sample preparation or zero operator involvement.
The operator may still need to perform certain preparation steps depending on the platform.
Therefore, “sample-to-result” should not automatically be interpreted as zero sample preparation + zero operator involvement.
The actual workflow should always be assessed from the specific system’s instructions for use.
Why move molecular testing closer to the patient?
The potential value of decentralised molecular testing is not simply that the instrument is smaller.
The more important consideration is whether changing the location and workflow of testing can improve the overall diagnostic pathway.
In a conventional model:
Conventional / Centralised Pathway
Decentralised Pathway
Potential advantages depend on the application and implementation but may include reduced specimen transport requirements, simplified workflow, improved access to molecular testing and the possibility of making results available closer to the clinical encounter.
The value therefore comes from workflow and access—not miniaturisation alone.
Where can molecular POCT be useful?
Molecular POCT can potentially support several testing environments, depending on the assay, platform, intended use and local requirements.
STI & Reproductive Health
Molecular testing for infections such as Chlamydia trachomatis and Neisseria gonorrhoeae can traditionally depend on centralised laboratory NAAT workflows. Decentralised molecular testing can potentially bring accurate pathogen detection closer to sexual and reproductive-health services. This is particularly relevant where the diagnostic pathway aims to reduce the gap between patient presentation, testing and appropriate management.
Explore STI & Reproductive Health →Respiratory Infections
Integrated molecular platforms can enable respiratory pathogens to be investigated closer to emergency, acute-care or other decentralised environments. Depending on the platform, testing may range from focused pathogen detection to broader multiplex panels. The appropriate panel still depends on the diagnostic question, patient population, specimen and clinical setting.
Explore Respiratory Molecular Diagnostics →HPV & Women’s Health
Molecular HPV testing is increasingly important in cervical-cancer screening strategies. Decentralised or simplified molecular workflows may create opportunities to expand access to molecular testing in settings where conventional laboratory infrastructure or specimen transport creates operational barriers. Implementation still depends on the intended use, screening programme and validated specimen/workflow.
Explore HPV & Women’s Health →Other Infectious-Disease Applications
The same principle can extend to other infectious diseases where bringing molecular detection closer to the point of need may improve diagnostic access or workflow. However, the suitability of POCT should be evaluated application by application rather than assumed from the platform alone.
Does molecular POCT replace the central laboratory?
Usually, this is the wrong way to frame the question.
Central laboratories provide capabilities that may include high-throughput testing, broad assay menus, specialised expertise, complex testing, confirmatory workflows and quality-management infrastructure.
Molecular POCT solves a different problem:
How can appropriate molecular testing be made available closer to where a result is needed?
The two models can therefore be complementary.
A healthcare network might use:
Central Laboratory Testing
for high-volume and specialised molecular diagnostics
Decentralised / Near-POC Testing
for selected services or locations
POC Molecular Testing
where near-patient access and simplified workflow provide meaningful value
The appropriate test in the appropriate setting
The objective is not necessarily to move every molecular test out of the laboratory.
It is to place the appropriate test in the appropriate setting.
What should laboratories evaluate before implementing molecular POCT?
A small instrument and a simple cartridge do not remove the need for laboratory governance.
Before implementing a molecular POCT workflow, laboratories and healthcare organisations should consider several dimensions.
Intended use
Which pathogen, condition or clinical question is the assay designed to address?
Specimen
Which specimen types are validated, and what collection or preparation is required?
Workflow
How many operator steps are required from specimen to result?
Operator
Who will perform the test, and what training or competency assessment is required?
Testing environment
Can the system operate appropriately in the intended clinic, decentralised laboratory or near-patient environment?
Quality management
How will internal controls, external quality assessment, maintenance, competency and error handling be managed?
Result interpretation
How will results be communicated, interpreted and integrated into the clinical pathway?
Connectivity and governance
How will results enter the laboratory or healthcare information system, and how will patient identification, traceability and data governance be maintained?
Service and support
What application support, troubleshooting, maintenance and supply continuity are required to sustain the testing service?
Successful molecular POCT therefore requires more than selecting an instrument.
These Must Function Together
Technology + Workflow + Quality + People + Connectivity + Support
Simple does not mean uncontrolled
One of the attractions of molecular POCT is workflow simplification.
But a simplified assay still produces a clinical diagnostic result.
Testing closer to the patient may involve operators outside the conventional molecular laboratory, making clearly defined procedures, training, competency, quality assurance and result governance particularly important.
Therefore:
Simple Does Not Mean Uncontrolled
Simplified workflow should reduce operational complexity — not laboratory responsibility.
Clinical laboratories can continue to play an important role in evaluating technologies, establishing quality systems, supporting operators and overseeing decentralised testing networks.
Molecular POCT as a testing model
Perhaps the most useful way to understand molecular POCT is not as a category of small PCR machines.
It is a diagnostic delivery model.
The technology matters, but so do:
Where
the test is performed
Who
performs it
How
the specimen is processed
What
information the assay provides
When
the result becomes available within the patient pathway
How
quality is maintained
How
the result leads to appropriate action
Molecular POCT is a diagnostic delivery model — not simply a category of small PCR instruments.
A technically impressive molecular platform creates limited value if it does not fit the environment in which it is deployed.
Conversely, an appropriately selected and implemented system can extend molecular diagnostic capability beyond the conventional central laboratory.